Please report adverse events to the Belgian Centre for Pharmacovigilance for medicines for Human use of the Federal Agency for Medicines and Health Products via adr@afmps.be or via www.notifieruneffetindesirable.be or to GlaxoSmithKline Pharmaceuticals s.a./n.v. via be.medinfo@gsk.com.